Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada

Similar Items

• The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
  od: MacRae, Megan, i dr.
  Izdano: (2014)
• Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
  od: Forgie, Jennifer, i dr.
  Izdano: (2014)
• Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
  od: O’Quinn, John, i dr.
  Izdano: (2014)
• Use of Omalizumab to treat a nine-year old, with steroid-dependent, allergic asthma, adrenal insufficiency and vertebral compression fractures due to steroid induced severe osteoporosis
  od: Ring, Alicia, i dr.
  Izdano: (2011)
• Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis
  od: Baker, Dana L., i dr.
  Izdano: (2015)